Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03340506
Title Dabrafenib and/or Trametinib Rollover Study
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Trametinib

Dabrafenib

Dabrafenib + Trametinib

Age Groups: child | adult | senior
Covered Countries USA


No variant requirements are available.